The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: A meta-analysis

Biomarkers

Volumn 19, Issue 1, 2014, Pages 56-62

  Chen, Yi Jing ^a   Hu, Fei ^a   Li, Chun Yan ^a   Fang, Jue Min ^a   Chu, Li ^a   Zhang, Xi ^a   Xu, Qing ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Asians; Gene polymorphism; Irinotecan; Neutropenia; UGT1A1

Indexed keywords

BIOLOGICAL MARKER; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

ARTICLE; ASIAN; DISEASE SEVERITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS; NEUTROPENIA; CHEMICALLY INDUCED DISORDER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; RISK;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HUMANS; NEUTROPENIA; POLYMORPHISM, GENETIC; RISK;

EID: 84893319290     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.867534     Document Type: Article

References (33)

1. Akiyama Y, Fujita K, Nagashima F, et al. (2008). Genetic testing for UGT1A1*28 and*6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol 19:2089-90.
2. Choi YH, Kim TW, Kim KP, et al. (2012). A phase II study of clinical outcomes of 3-week cycles of irinotecan and s-1 in patients with previously untreated metastatic colorectal cancer: Influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. Oncology 82:290-7.
3. Fuchs CS, Moore MR, Harker G, et al. (2003). Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807-14.
4. Fukui T, Mitsufuji H, Kubota M, et al. (2011). Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent. Oncol Lett 2:923-8.
5. Gao J, Zhou J, Li Y, et al. (2013). UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol 30:604-9.
6. Hall D, Ybazeta G, Destro-Bisol G, et al. (1999). Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenet Genome 9:591-606.
7. Han JY, Lim HS, Shin ES, et al. (2006).comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin On col 24:2237-44.
8. Hazama S, Nagashima A, Kondo H, et al. (2010). Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci 101:722-7.
9. Hu ZY, Yu Q, Pei Q, et al. (2010). Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: Low doses also increase risk. Clin Cancer Res 16:3832-42.
10. Inoue K, Sonobe M, Kawamura Y, et al. (2012). Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. Tohoku J Exp Med 229:107-14.
11. Jo JC, Lee JL, Ryu MH, et al. (2012). Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. Br J Cancer 106:1591-7.
12. Liu X, Cheng D, Kuang Q, et al. (2013). Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: A meta-analysis in Caucasians. Pharmacogenom J. doi: 10.1038/tpj.2013.10.
13. Marsh S, Hoskins JM. (2010). Irinotecan pharmacogenomics. Pharmacogenomics 11:1003-10.
14. Minami H, Sai K, Saeki M, et al. (2007). Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms i n Japanese: Roles of UGT1A1*6 and*28. Pharmacogenet Genom 17:497-504.
15. Okazaki K, Watanabe T, Saito I, et al. (2012). Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genoty ped patients: A retrospective survey of irinotecan. Yakugaku zasshi: J Pharmaceut Soc Jpn 132:231-6.
16. Okuyama Y, Hazama S, Nozawa H, et al. (2011). Prospective phase II study of FOLFIRI for mCRC in Japan, in cluding the analysis of UGT1A1*28/ *6 polymorphisms. Japan J Clin Oncol 41:477-82.
17. Onoue M, Terada T, Kobayashi M, et al. (2009). UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14:136-42.
18. Premawardhena A, Fisher CA, Liu YT, et al. (2003). The global distribution of length polymorphisms of the promoters of the glucuronos yltransferase 1 gene (UGT1A1): Hematologic and evolutionary implications. Blood Cells Mol Dis 31:98-101.
19. Sai K, Saito Y, Sakamoto H, et al. (2008). Importance of UDPglucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 261:165-71.
20. Satoh T, Ura T, Yamada Y, et al. (2011). Genotype-directed, dosef inding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102:1868-73.
21. Seo BG, Kwon HC, Oh SY, et al. (2009).comprehensive analysis of excision repair complementati on group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncology Rep 22:127-36.
22. Staessen JA, Kuznetsova T, Acceto R, on behalf of the OASIS-HT Investigators. (2005). FDA clears Third Wave pharmacogenetic test. Pharmacogenomics 6:671-2.
23. Sugiyama T, Hirose T, Kusumoto S, et al. (2010). The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Oncology Res 18:337-42.
24. Sunakawa Y, Ichikawa W, Fujita K, e t al. (2011). UGT1A1*1/ *28 and*1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 68:279-84.
25. Takano M, Kato M, Yoshikawa T, et al. (2009). Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: A prospective multi-institutional study. Oncology 76:315-21.
26. Thakkinstian A, McElduff P, D?Este C, et al. (2005). A method for metaanalysis of molecular association studies. Stat Med 24:1291-306.
27. Wang Y, Shen L, Xu N, et al. (2012). UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol: WJG 18:6635-44.
28. Yamamoto N, Takahashi T, Kunikane H, et al. (2008). Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Therapeut 85:149-54.
29. Yong WP, Innocenti F, Ratain MJ. (2006). The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 62:35-46.
30. Zhou CF, Ma T, Su Y, et al. (2013). UGT1A1 gene polymorphisms and the toxicities of FOLFI RI in Chinese Han patients with gastrointestinal cancer. Anti-Cancer Agents Med Chem-Anti-Cancer Agents 13: 235-41.
31. Zintzaras E. (2010). The generalized odds ratio as a measure of genetic risk effect in the analysis an d meta-analysis of association studies. Statist Appl Genet Mol Biol 2010;9:Article 21.
32. Zintzaras E. (2013). Examining the stability of genetic risk effect as evidence accumulates in the context of meta-analysis.comput Biol Med 43:1293-9.
33. Zintzaras E, Lau J. (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61:634-45.